Esophageal Cancer
Conditions
Interventions
Radiotherapy(2Gy/5day/week) is begun within 24 hours of the administration of chemotherapy, and continue for 4 weeks(40Gy). Combination chemotherapy consists of docetaxel (25,30,35,40 mg/m2/day, day
Sponsors
Department of Surgical Oncology, Division of Clinical and Experimental Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically proven esophageal carcinoma. 2.Lesion located within the radiation field. 3.Primary lesion with penetration of muscularis propiria, excluding T4 lesion and distant metastasis. 4.Measurable lesion 5.No previous therapy against esophageal cancer. 6.No previous radiotherapy within the radiation field. 7.ECOG Performance status 0 or 1 8.Aged 20 to 75 years old 9.Expected to survive more than 3 months 10.Written informed consent
Exclusion criteria
Exclusion criteria: 1.History of hypersensitivity to DOC, CDDP, 5-FU, or polysorbate 80 2.With severe complication 3.Infection with fever elevation 4.Motor paralysis, peripheral neuropathy or edema 5.Pleural or pericardial effusion that requires treatment 6.Simultaneous or metachronous (within 5 years) double cancers. 7.Pregnant or lactating women 8.Interstitial pneumonia or fibroid lung 9.Psychosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PhaseI:Incidence of dose limiting toxicity PhaseII:Histopathological response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| PhaseI:Adverse events,Histopathological response rate PhaseII:Adverse events, Disease-free survival, Overall survival | — |
Countries
Japan
Contacts
Public ContactManabu Emi
Research Institute for Radiation Biology and Medicine Hirosima University Surgical Oncology
Outcome results
None listed